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Pelation Between Lipoprotein(a) and
ibrinogen and Serial Intravascular Ultrasound
laque Progression in Left Main Coronary Arteries
arc Hartmann, MD,* Clemens von Birgelen, MD, PHD,* Gary S. Mintz, MD,‡ Martin G. Stoel, MD,*
olger Eggebrecht, MD,† Heinrich Wieneke, MD,† Martin Fahy, MSC,‡ Till Neumann, MD,†
ob van der Palen, MSC,* Hans W. Louwerenburg, MD,* Patrick M. J. Verhorst, MD, PHD,*
aimund Erbel, MD†
nschede, the Netherlands; Essen, Germany; and New York, New York
OBJECTIVES Patients with elevated lipoprotein(a) [Lp(a)] and fibrinogen levels have an increased risk of
coronary heart disease and adverse cardiovascular events. There is evidence that coronary
plaque progression is linked to a higher risk for future cardiovascular events.
BACKGROUND There are no data demonstrating a relation between Lp(a), fibrinogen, and directly measured
coronary plaque progression over time.
METHODS We performed a retrospective analysis of serial intravascular ultrasound (IVUS) studies of 60
left main stems (18 9 months apart) to evaluate plaque progression in relation to Lp(a) and
fibrinogen levels and association with adverse cardiovascular events.
RESULTS There was a positive correlation between Lp(a) (r  0.58; p  0.0001), fibrinogen (r  0.48;
p  0.0001), and changes in plaque-plus-media area. Patients with plaque progression (n 
41) had higher Lp(a) (30  26 mg/dl vs. 14  9 mg/dl; p  0.0012) and fibrinogen (295 
88 mg/dl vs. 240  72 mg/dl; p  0.019) levels than patients with plaque regression (n 
19). Multivariate linear regression analysis showed Log Lp(a) (regression coefficient  9.45;
p  0.0008) but not fibrinogen to be independently associated with plaque progression. A
total of 19 patients suffered from adverse cardiovascular events; they had higher Lp(a) (44  30
mg/dl vs. 16  12 mg/dl; p  0.0001) and fibrinogen (342  73 mg/dl vs. 248  76 mg/dl;
p  0.0001) levels. Multivariate logistic regression analysis showed Log Lp(a) (odds ratio 10.20,
95% confidence interval 2.36 to 44.13; p  0.0019) and fibrinogen (odds ratio 1.01, 95%
confidence interval 1.00 to 1.03; p  0.018) were independently associated with adverse
cardiovascular events.
CONCLUSIONS Serial IVUS showed a positive correlation between Lp(a) and fibrinogen levels and plaque
progression. Lp(a), but not fibrinogen, remains independently associated with plaque
progression. In addition, the present data suggest a considerable incremental value of Lp(a)
in predicting cardiovascular risk. (J Am Coll Cardiol 2006;48:446–52) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.047American College of Cardiology Foundation
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qipoprotein(a) [Lp(a)] and fibrinogen have been shown to
erve as predictors of coronary heart disease and fatal
ardiovascular events (1–10). Patients with elevated Lp(a)
nd fibrinogen levels have an increased risk of coronary
eart disease (11,12) and cardiovascular events (12–14).
here is evidence that plaque progression in coronary
rteries is linked to a higher risk of future fatal or nonfatal
ardiovascular events (15,16). Lipoprotein(a) is associated
ith plaque progression, as indirectly assessed by lumen
hanges in short-term (17,18) and long-term (19,20) an-
iographic follow-up, and with calcium score changes as
easured by sequential electron beam computerized tomog-
aphy (21). There are no data demonstrating directly the
elation between Lp(a), fibrinogen, and coronary plaque
rogression.
Intravascular ultrasound (IVUS) imaging permits mea-
urements of total vessel, lumen, and plaque dimensions in
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etherlands; †Department of Cardiology, Essen University, Essen, Germany; and the
Cardiovascular Research Foundation, New York, New York.3
Manuscript received February 10, 2006; revised manuscript received March 21,
006, accepted March 28, 2006.ivo (22). Serial IVUS is an ideal tool to directly assess
rogression or regression of atherosclerotic plaques in native
oronary arteries in relation to serum parameters (23–25). In
he present observational study we retrospectively analyzed
erial IVUS (12 months) data of nonstenotic left main
oronary arteries to test whether Lp(a) and fibrinogen levels
redict the progression of coronary atherosclerosis and the
nset of adverse cardiovascular events (beyond the informa-
ion provided by classic risk factors) and whether potential
elations are independent of each other.
ETHODS
tudy population. We performed a retrospective analysis of
p(a) and fibrinogen levels in relation to serial IVUS studies of
therosclerotic left main coronary plaques in a population that
as been reported previously (25). All plaques were de novo,
emodynamically nonsignificant, and met the following
riteria: 1) serial high-quality IVUS of the entire left main
rtery 12 months apart; 2) calcifications that did not limit
uantitative assessment of vessel cross-sectional area (CSA);
) nonostial plaque location; 4) angiographic lumen diam-
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August 1, 2006:446–52 Lp(a) and Fibrinogen Versus IVUS Plaque Progressionter stenosis 30% (“worst view” visual assessment); and 5)
o intervention in the very proximal left anterior descending
r circumflex coronary arteries, because these interventions
ould have affected the left main artery. Patients were
xamined in the Essen University Cardiac Catheterization
aboratory (a tertial referral center) with a follow-up of 18 
months (median 14 months, range 12 to 50 months). As
reviously reported, this represents consecutive patients who
nderwent initial IVUS examination during coronary inter-
ention and then returned after a 1- to 2-year period for
epeat IVUS examination (25). No patient had a myocardial
nfarction within 3 months before the index examination.
t Essen University, patients with previous IVUS who
eturned for recatheterization were routinely examined with
VUS as part of the clinical protocol. In none of these
atients was IVUS performed as part of another study. This
VUS study was approved by the Local Council on Human
esearch, and all patients signed a written informed consent
orm as approved by the local medical ethics committee.
ardiovascular risk factors, parameters, and medication.
n our laboratory we record demographics, cardiovascular
isk factors, medications, and results of key laboratory tests
f patients examined with IVUS. All baseline blood samples
ere collected from the same site (periphereal vein) 27 
h before percutaneous catheterization (26) and analyzed in
he central laboratory of Essen University according to
nternational standards. Plasma concentrations of total cho-
esterol, low-density lipoprotein cholesterol (LDL-C),
igh-density lipoprotein cholesterol (HDL-C), and triglyc-
rides were measured by standard enzymatic methods. Total
holesterol/HDL-C and LDL-C/HDL-C ratios were cal-
ulated. Lipoprotein(a) levels were quantitated by nephe-
ometry after addition of an antiserum (Behringwerke,
arburg, Germany) (27). Fibrinogen was measured by
etermining the coagulation time of prediluted citrated
lasma in the presence of a large amount of thrombin
Behringwerke). Baseline data of all laboratory variables
ere used for statistical analyses. Cardiovascular risk factors
hat were recorded included diabetes mellitus and hyperten-
ion (both medication-dependent only), history of smoking,
nd family history of coronary artery disease. Medications
ere recorded only if drugs were taken for 50% of the
ollow-up interval (e.g., clopidogrel for 4 weeks was not
Abbreviations and Acronyms
CI  confidence interval
CSA  cross-sectional area
EEM  external elastic membrane
HDL  high-density lipoprotein
IVUS  intravascular ultrasound
LDL  low-density lipoprotein
Lp(a)  lipoprotein(a)
PCI  percutaneous coronary intervention
P&M  plaque plus mediaabulated). cVUS imaging. The IVUS imaging was performed as
reviously described (25). In brief, IVUS studies were
erformed during percutaneous coronary interventions
PCI) of middle or distal left anterior or circumflex arteries
fter intracoronary injections of 200 g nitroglycerin with
ommercially available IVUS systems: a mechanical sector
canner (Boston Scientific, San Jose, California) incorporat-
ng a 30-MHz single-element beveled transducer or a
olid-state device (Endosonics, Rancho Cordova, Califor-
ia). Importantly, at Essen University, if a patient under-
oes imaging with one IVUS system during an index
rocedure, the same IVUS system is used at follow-up. Slow
ontinuous pullbacks were generally performed using a
otorized pullback device (at 0.5 mm/s). In addition, a
edicated image-in-image system (Echo-Map; Siemens,
rlangen, Germany) was used to record the “angiographic”
osition of the IVUS probe together with the corresponding
VUS image (28).
uantitative IVUS analysis. The left main target site
mage slice was determined from the initial IVUS study as
reviously described (25); this was the site with the smallest
umen CSA within the plaque. Exact matching of the target
ite on initial and follow-up IVUS studies was ensured using
ide-by-side comparison of end-diastolic IVUS images of
he two IVUS sequences along with the pullback speed, the
perators’ recorded comments (on videotape), and charac-
eristic calcifications, vascular and perivascular landmarks,
nd plaque shapes. If required, X-ray sequences of the
edicated image-in-image system (Echo-Map) were revis-
ted to optimize matching (28).
The lumen CSA was measured by tracing the leading
dge of the intima. The external elastic membrane (EEM)
SA was measured by tracing the leading edge of the
dventitia. Plaque plus media (P&M) CSA was calculated
as EEM  lumen CSA). Extrapolation of the EEM
oundary behind calcium was possible if each individual
alcific deposit did not shadow 75° of the adventitial
ircumference. To compensate for variations in follow-up
ntervals and to obtain comparable data, we calculated
bsolute and relative changes () between initial and
ollow-up IVUS data; measurements were normalized for
he length of the follow-up period (changes per year) and
aseline variables.
tatistical analysis. Analyses were performed with SPSS
0.0.7 (SPSS Inc., Chicago, Illinois). Dichotomous data are
resented as frequencies. Quantitative data are presented as
ean  1 SD and were compared using Student t test,
ann-Whitney U test, and regression analysis. Correlation
nalyses were performed with nonparametric Spearman test
r  Spearman correlation coefficient). Because the distri-
ution of Lp(a) was skewed it was log transformed (Log) to
btain a normal distribution and more reliable estimates for
ultivariate regression analyses. A p value of 0.05 wasonsidered significant.
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Lp(a) and Fibrinogen Versus IVUS Plaque Progression August 1, 2006:446–52ESULTS
emographics, medication, and laboratory testing of
atients. Demographics, medication, and baseline labora-
ory testing of the study population (n  60) are presented
n Table 1. We found a positive correlation (r  0.49; 95%
onfidence interval [CI] 0.27 to 0.66; p  0.0001) between
p(a) (median 14.5 mg/dl, range 6.2 to 125.0 mg/dl) and
brinogen levels (median 271.0 mg/dl, range 110.0 to 510.5
g/dl).
elation between Lp(a) and serial IVUS data. There was
positive correlation between annual changes in P&M CSA
ersus Lp(a) levels (r 0.58; 95% CI 0.39 to 0.73; p 0.0001)
Fig. 1). There was a negative correlation between annual
able 1. Patient Demographics, Medications, and
aboratory Testing
All Patients
(n  60)
VUS follow-up, months 18  9
ge, yrs 58  8
en, n (%) 50 (83)
ody mass index, kg/m2 27  3
revious myocardial infarction, n (%) 21 (35)
moker, n (%) 16 (27)
ystemic arterial hypertension, n (%) 43 (72)
iabetes, n (%) 8 (13)
amily history of coronary disease, n (%) 14 (23)
essels diseased, n (%)
1 28 (47)
2 16 (27)
3 16 (27)
linical syndrome, n (%)
table angina CCS class
I 17 (28)
II 29 (48)
III 9 (15)
IV 5 (8)
edication, n (%)
Acetylsalicylic acid 60 (100)
ACE inhibitors 22 (37)
Angiotensin receptor antagonists 2 (3)
Beta-blockers 36 (60)
Calcium-channel blockers 17 (28)
Diuretics 18 (30)
Fibrates 3 (5)
Insulin 2 (3)
Nitrates 36 (60)
Oral antidiabetics 3 (5)
Statins 49 (82)
aboratory tests*
Lipoprotein(a), mg/dl 25  23
Fibrinogen, mg/dl 278  87
Total-C, mg/dl 199  39
LDL-C, mg/dl 127  45
HDL-C, mg/dl 48  15
Total-C/HDL-C (ratio) 4.5  1.6
LDL-C/HDL-C (ratio) 2.9  1.5
Triglycerides, mg/dl 127  74
Blood sampling 27  8 h before index examination.
ACE  angiotensin-converting enzyme; C  cholesterol; CCS  Canadian
ardiovascular Society; HDL  high-density lipoprotein; IVUS  intravascular
ltrasound; LDL  low-density lipoprotein.hanges in lumen CSA versus Lp(a) levels (r  0.24; 95% LI 0.55 to 0.10; p  0.007) (data not shown) and no
orrelation between annual changes in EEM CSA versus
p(a) levels (r  0.01; 95% CI 0.25 to 0.26; p  0.95)
data not shown). Patients with P&M CSA increase (n 
1) had significantly higher Lp(a) levels than patients with
&M CSA decrease (n  19) (30  26 mg/dl vs. 14  9
g/dl; p  0.0012).
elation between fibrinogen and serial IVUS data. There
as a positive correlation between annual changes in P&M
SA versus fibrinogen levels (r  0.48; 95% CI 0.25 to
.65; p  0.0001) (Fig. 1). There was no significant
orrelation between annual changes in lumen CSA versus
brinogen levels (r  0.23; 95% CI 0.46 to 0.02; p 
.07) (data not shown) and no correlation between annual
hanges in EEM CSA versus fibrinogen levels (r  0.11;
5% CI0.15 to 0.35; p 0.42) (data not shown). Patients
ith P&M CSA increase (n  41) had significantly higher
brinogen levels than patients with P&M CSA decrease
n  19) (295  88 mg/dl vs. 240  72 mg/dl; p  0.019).
ultivariate analysis of predictors of P&M CSA increase.
ultivariate linear regression analysis was used to determine
redictors of the increase in P&M CSA (Table 2). The
ollowing were tested in the multivariate model: Log Lp(a),
brinogen, LDL-C, HDL-C, total cholesterol, total
holesterol/HDL-C ratio, LDL-C/HDL-C ratio, smok-
ng, hypertension, diabetes, family history, age, and use of
tatins (LDL-C, HDL-C, and smoking were shown in a
revious publication to be univariate predictors of the
ncrease in P&M CSA in these patients [16]). Independent
redictors were Log Lp(a) (p  0.0008) and smoking (p 
.0001); LDL-C (p  0.078) showed a trend, whereas
brinogen was not an independent predictor (Table 2).
p(a) and fibrinogen and adverse cardiovascular events.
uring follow-up, 6 patients (10%) suffered from acute
yocardial infarction, 7 (12%) from unstable angina, and 6
10%) from PCI of a new de novo coronary lesion. The mean
nterval between baseline laboratory test and adverse event
uring follow-up was 450  98 days. Patients with adverse
ardiovascular events (n  19) had higher Lp(a) (44  30
g/dl vs. 16  12 mg/dl; p  0.0001) and fibrinogen levels
342  73 mg/dl vs. 248  76 mg/dl; p  0.0001) than
atients without adverse events (n  41) (Fig. 2, Table 3).
n addition, patients with adverse events had significantly
igher total cholesterol/HDL-C and LDL-C/HDL-C ra-
ios and significantly more annual increase in P&M CSA
han patients without events (Table 3).
ultivariate analysis of predictors of adverse cardiovas-
ular events. Multivariate logistic regression analysis was
sed to determine predictors of adverse cardiovascular
vents during follow-up (Table 4). The following were
ested in the multivariate model: Log Lp(a), fibrinogen,
DL-C, HDL-C, total cholesterol, total cholesterol/
DL-C ratio, LDL-C/HDL-C ratio, smoking, hyperten-
ion, diabetes, familiy history, age, use of statins, and
ncrease in P&M CSA. Independent predictors were Log
p(a) (p  0.0019) and fibrinogen (p  0.018) (Table 4).
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August 1, 2006:446–52 Lp(a) and Fibrinogen Versus IVUS Plaque ProgressionISCUSSION
p(a) and coronary plaque progression. Previous studies
evealed Lp(a) as a predictor of coronary heart disease (3,7),
ngiographic severity, and extent of the disease process (3).
owever, other studies failed to demonstrate an association
etween Lp(a) and cardiovascular disease (29,30). In good
greement with our findings, Lp(a) levels showed a strong
orrelation with serial plaque progression assessed in previ-
us angiographic (17–20) and electron beam tomographic
tudies (21). Uchida et al. (18) showed Lp(a) to be an
ndependent predictor of angiographic lesion progression at
months follow-up, and Matsumoto et al. (19) showed that
he Lp(a) level was significantly associated with angio-
raphic disease progression after more than 24 months. In
upport of this, we found a positive correlation between
p(a) levels versus annual changes in P&M CSA. In
ddition to smoking, Lp(a) was an independent predictor of
laque progression in a multivariate analysis (LDL-C
howed only a trend). The cluster of Lp(a) levels around 10
g/dl does not permit defining an exact threshold below
hich no plaque progression occurs. However, the mean Lp(a)
evel of patients with plaque progression was 30 mg/dl, whereas
t was 14 mg/dl in patients without plaque progression (p 
.0012). Such Lp(a) values (around 30 mg/dl) were also found
n previous serial angiographic studies to be associated with
ong-term plaque progression (19).
igure 1. Lipoprotein(a) and fibrinogen serum levels versus annual chan
orrelation coefficient. Dotted regression lines were derived from linear re
able 2. Multivariate Predictors of Plaque Plus Media
ross-Sectional Area Increase
Multivariate
Predictors*
Regression
Coefficient
Standard
Error p
ntercept 30.4322 7.8713 0.0003
og lipoprotein(a) 9.4452 2.6743 0.0008
moker 17.1133 4.1103 0.0001
DL-cholesterol 0.0758 0.0422 0.0778
Multivariate predictors are chosen by stepwise linear regression with entry/stay
P
p
riteria of 0.2/0.1.
LDL  low-density lipoprotein.The pathophysiologic role of Lp(a) in atherosclerotic
isease progression is explained by the accumulation of
p(a) in the vessel wall and its ability to promote cholesterol
ccumulation in macrophages forming foam cells and sub-
equent fatty streaks (31,32) and to promote smooth muscle
ell proliferation and migration in atherosclerotic lesions by
nactivating transforming growth factor-beta (33). Lipopro-
ein(a) is considered to have an inhibitory effect on fibrino-
ytic mechanisms owing to its structural similarity to plas-
inogen causing competition with plasminogen activators;
ntraluminal thrombus formation may also cause reparative
roliferative response of the vascular wall (17,31,32).
igure 2. Lipoprotein(a) and fibrinogen serum levels in patients with and
ithout adverse cardiovascular events. AMI  acute myocardial infarction;
plaque plus media (P&M) cross-sectional area (CSA). r  Spearman
on analysis.ges inCI  percutaneous coronary intervention; UAP  unstable angina
ectoris.
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Lp(a) and Fibrinogen Versus IVUS Plaque Progression August 1, 2006:446–52ibrinogen and coronary plaque progression. It has been
emonstrated that fibrinogen may also be associated with
everity and extent of coronary atherosclerosis (8,9) and
ith electron beam tomography-assessed calcium score
10). In support of this, we found a positive correlation
etween fibrinogen levels versus annual changes in P&M
SA. However, fibrinogen was not an independent predic-
or of plaque progression in a multivariate analysis. Fibrin-
gen affects blood rheology and platelet aggregation, which
lay a role in atherogenesis (34). Nevertheless, the mecha-
isms by which fibrinogen may promote atherosclerosis
rogression remains to be determined (6).
ascular remodeling. In the present study we found no
elation between Lp(a) or fibrinogen levels versus actual
rterial remodeling (EEM CSA). One nonserial IVUS
tudy found no relation between Lp(a) levels and the
emodeling index, defined as the ratio of the lesion EEM
SA to the reference EEM CSA (35). In addition, other
lood chemistries that are associated with atherogenesis
total cholesterol, LDL-C, HDL-C, triglycerides, and
-reactive protein) also had no impact on arterial remod-
ling (35).
Table 3. Laboratory Tests and Serial IVUS Da
Points and/or Revascularization Procedures Du
Patients With Cl
End Points and
Revascularizati
Procedures (n 
Laboratory tests*
Lipoprotein(a), mg/dl 44  30
Fibrinogen, mg/dl 342  73
Total-C, mg/dl 208  39
LDL-C, mg/dl 140  42
HDL-C, mg/dl 44  18
Total-C/HDL-C (ratio) 5.2  1.7
LDL-C/HDL-C (ratio) 3.8  1.6
Triglycerides, mg/dl 104  55
Serial IVUS
P&M CSA/yr, mm2 1.7  1.0
P&M CSA/yr, % 24.0  16.6
Lumen CSA/yr, mm2 0.8  4.0
Lumen CSA/yr, % 3.1  20.5
EEM CSA/yr, mm2 0.9  4.3
EEM CSA/yr, % 5.5  15.7
*Blood sampling 27  8 h before index examination; †compa
  change; CSA cross-sectional area; EEM externa
as in Table 1.
able 4. Multivariate Predictors of Adverse Cardiovascular
vents (Clinical End Points and/or Revascularization
rocedures) During Follow-Up
Multivariate
Predictors*
Odds Ratio
(95% CI)
Regression
Coefficient
Standard
Error p
ntercept 7.2948 3.9502 0.0648
og lipoprotein(a) 10.20 (2.36–44.13) 2.3228 0.7471 0.0019
ibrinogen 1.01 (1.00–1.03) 0.0141 0.0060 0.0183
Multivariate predictors are chosen by stepwise logistic regression with entry/stays
riteria of 0.2/0.1.
CI  confidence interval.elation between Lp(a), fibrinogen, and adverse cardio-
ascular events. A correlation between Lp(a) and fibrino-
en concentrations has been reported (36) but was not
onsistently found in the majority of previous studies (37).
n the present study population, Lp(a) levels correlated
irectly with fibrinogen levels. In vitro studies showed that
ver time Lp(a) binds with fibrinogen in a concentration-
ependent manner (38). The deposition of Lp(a) within the
brin clot is believed to be a contributing factor in athero-
enesis, promoting plaque progression (31,32,38). Study
atients with plaque progression had significantly higher
p(a) and fibrinogen levels. However, only Lp(a) was an
ndependent predictor of plaque progression.
On the other hand, the association between Lp(a) and
brinogen levels may indicate a multiple unstable plaque
henotype (advanced disease); fibrinogen may be elevated as
art of the acute phase response, and Lp(a) has also been
hown to rise after plaque destabilization (26). Two clinical
tudies showed that patients with elevated serum Lp(a)
evels, when associated with high fibrinogen levels, had a
ignificantly increased cardiovascular disease risk (11,12).
eak serum levels of Lp(a) and fibrinogen seem to coincide
ith the morning peak frequencies of myocardial infarction
nd stroke (14). Accordingly, we found that patients with
dverse cardiovascular events had significantly higher serum
evels of both Lp(a) and fibrinogen than patients who were
vent free during follow-up. In a multivariate model, Lp(a)
nd fibrinogen were independent predictors of adverse
ardiovascular events. Our data suggest in particular an
ncremental value of Lp(a) in predicting cardiovascular risk
beyond the information provided by classic risk factors).
tudy limitations. By most standards, this was a large
Patients With and Without Clinical End
Follow-Up
Patients Without Clinical
End Points and/or
Revascularization
Procedures (n  41) p
16  12 0.0001†
248  76 0.0001‡
196  38 0.27‡
120  45 0.10‡
50  13 0.20‡
4.2  1.4 0.02‡
2.6  1.4 0.02‡
137  80 0.11‡
0.3  1.5 0.001‡
5.6  16.5 0.0002‡
0.1  2.4 0.41‡
0.9  16.9 0.43‡
0.2  2.8 0.48‡
1.6  11.0 0.27‡
ing Mann-Whitney U test; ‡compared using Student t test.
c membrane; P&M plaque plus media; other abbrevationsta of
ring
inical
/or
on
19)
red userial IVUS study; however, all current studies with long-
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August 1, 2006:446–52 Lp(a) and Fibrinogen Versus IVUS Plaque Progressionerm serial IVUS assessment of atherosclerosis are limited to
relatively small number of patients. This was a retrospec-
ive analysis, and we included only patients with established
oronary artery disease and repeat cardiac catheterization
12 months after baseline. About a third of the subjects
xperienced a clinical event during a follow-up of only 18
onths in spite of adequate therapy and prevention. Ac-
ordingly, this is a very high-risk group. Because of this
election bias, the findings of the current study may not be
pplicable to a standard population with coronary artery
isease or even the general population without established
isease. Other superior markers of inflammation (e.g.,
igh-sensitivity C-reactive protein) were not available for
he present study population. We used 2 IVUS systems in
he present study; although this approach may have minor
hortcomings, every effort was taken to obtain the most
eliable data possible, as previously discussed in detail (25).
hree-dimensional analyses may be superior for the assess-
ent of coronary dimensions and provide volumetric data
39). We studied only left main artery disease as represen-
ative of nonintervened coronary segments.
onclusions. We found a positive correlation between
p(a) and fibrinogen levels versus annual changes in P&M
SA. Lipoprotein(a) was an independent predictor of
laque progression (regression coefficient  9.45), with a
ean Lp(a) level of 30 mg/dl in patients with plaque
rogression. Lipoprotein(a) and fibrinogen were indepen-
ent predictors of adverse cardiovascular events during
ollow-up in this group of patients. The data suggest in
articular a considerable incremental value of Lp(a) in
redicting cardiovascular risk.
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